Patients with moderate to severe COVID-19 outcomes on remdesivir according to baseline 4C mortality score.

ABSTRACT:

Background

Remdesivir was the first antiviral to show clinical benefit in patients with moderate-to-severe COVID-19. Previous trials demonstrated a faster time to recovery in hospitalized patients treated with remdesivir vs placebo. Current guidelines recommend treatment with remdesivir based on hospitalization status, oxygen requirements, and time from symptom onset. However, other factors may be evaluated to determine disease severity and risk for progression. The 4C mortality score is a validated, eight variable score that may be used to categorize patients by mortality risk at the time of hospital admission for COVID pneumonia. The objective of this study was to determine if the 4C mortality score may be used to predict which patients with moderate to severe COVID-19 would bene

SUBMITTER: Sellers J 

PROVIDER: S-EPMC9806928 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature